Now ideas for wellness

About Meiji

At a Glance

At a Glance

Get to know Meiji at a glance – from our core business to our most important numbers.

Year in Review

Year ended March 2021

Key Figures

Net Sales
¥1,191.7billion
4.9%
Operating Income
¥106.0billion
3.3%
Operating Income Ratio
8.9%
0.7percentage points
ROE
11.1%
1.3percentage points
Capital Expenditures
¥67.9billion
R&D Expenses
¥31.4billion

Breakdown by Segment

  • Food
  • Pharmaceuticals

Net Sales

Operating Income

Business Performance Analysis

Food
Net Sales
¥999.6billion
4.8%
Operating Income
¥87.4billion
0.1%
Income Analysis(Billions of yen)
Pharmaceuticals
Net Sales
¥193.6billion
5.2%
Operating Income
¥19.1billion
19.5%
Income Analysis(Billions of yen)

Capital Expenditures

  • Food
  • Pharmaceuticals

Food

¥56.4billion

Pharmaceuticals

¥11.3billion

Cash Dividends per Share / Dividend Payout Ratio

  • Cash Dividends per Share
  • Dividend Payout Ratio

Future Prospects

This is our Medium - Term Business Plan, FYE March 2022 through FYE March 2024.
Our consolidated earnings forecast is as follows:

  • FYE 3/2021
    Results
  • Net sales¥1,191.7 billion
  • Operating income¥106.0 billion
  • Operating income ratio8.9%
  • ROE11.1%
  • FYE 3/2024
    Targets
  • ¥1,080.0 billion
  • ¥120.0 billion
  • 11.1%
  • 11.0%

(as of May 18, 2021)

*The Accounting Standard for Revenue Recognition is applied from FYE March 2022. As such, the above targets are calculted based on assumption of accounting treatment changes related to revenue recognition.